Clinical Trials Logo

Clinical Trial Summary

Early diagnosis and appropriate treatment of tuberculous meningitis (TBM) are crucial steps to reduce morbidity and mortality. The WHO recommended to use Xpert MTB/RIF assay to diagnose pulmonary TB, pediatrics TB, extra pulmonary TB and rifampicin resistance. However, the data of accuracy in diagnosis of TBM is still lacking. This study aimed to find out the diagnostic performance of Xpert MTB/RIF assay for the diagnosis of tuberculous meningitis, especially in patients who presented with subacute lymphocytic meningitis.


Clinical Trial Description

Tuberculous meningitis (TBM) was the most serious manifestation of Mycobacterium tuberculosis infection with high rates of morbidity and mortality if treatment is delayed, especially in HIV-infected patients. The fatality rates increased to 60 percent compared to about one third in non-HIV infection. Prevalence and incidence of TBM worldwide is unclear. In 2015, the incidences of TBM were approximately 6-10 percent. In Northern Thailand, from the national survey programs, the prevalence rates of TBM were about 9.7 per 100,000 people, and TBM was the most common cause of death in extra-pulmonary TB patients with mortality rates about 0.54 per 100,000 people. However, these may be underreported due to diagnostic problems. Prompt and accurate diagnoses with early treatments, were the key elements to reduce deaths and disabilities in TBM. However, there were some major obstacles in the diagnostic procedures concerning the limitations, such as low sensitivity in conventional acid-fast bacilli (AFB) microscopy staining techniques or long turnaround times in gold-standard culture. Therefore, the delays in diagnoses lead to late managements and increased mortalities in TBM, especially in multidrug-resistance (MDR) cases. In the past, a lot of studies tried to solve these problems urgently, but the low frequency of confirmed cases and the absence of a consensus clinical case definition were the huge barriers causing a lack of progression in new clinical trials. In 2010, a uniform clinical case definition for use in clinical research about TBM was established. They used criteria from clinical characteristics, cerebrospinal fluid (CSF) examinations, neuroimaging studies, and evidence of tuberculosis elsewhere. Additionally, microbiological or pathological proof was used to classify the patients who had signs and symptoms of meningitis and were defined as definite, probable, possible, and not tuberculous meningitis. Since then, many clinical studies about TBM diagnosis were developed and made more convenient. The Xpert MTB/RIF assay was the closed-cartridge-based system heminested PCR for the diagnosis of tuberculosis (TB), and detecting the rifampicin resistant gene in sputum and the CSF. This can be used as a marker for MDR-TB, focused on endemic areas and HIV coinfection. This test has better diagnostic threshold levels (80-100 cfu/ml) than the 5,000 cfu/ml in AFB microscopy staining techniques, shorter duration for the results than conventional TB cultures, and more simplification than nucleic-acid amplification tests. Many studies about the diagnostic accuracy revealed that sensitivity and specificity of this new test varied from 50-86 % and 94-98 % depended on method, population, and laboratory techniques. There were some discussions about the application practicality in the diagnosis of TBM, such as in a large-population study in Vietnam that questioned the lower sensitivity and cost-effectiveness compared with conventional staining and culture. Subsequently, this newer rapid test was approved by WHO for TBM diagnosis. In Thailand, one of the countries with a high burden of tuberculosis, despite many advantages, use of this test was limited in CSF specimens due to the lack of data, including accuracy in CSF specimens for TBM diagnosis among the Thai population. This study aims to prospectively find out the diagnostic performance and accuracy of Xpert MTB/RIF in CSF samples from patients who presented with subacute lymphocytic meningitis in Northern Thailand, which can be the database for extending the study to cover patients in other parts of Thailand. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05781646
Study type Interventional
Source Chiang Mai University
Contact
Status Completed
Phase N/A
Start date January 1, 2015
Completion date December 31, 2016

See also
  Status Clinical Trial Phase
Completed NCT01371916 - Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF N/A
Active, not recruiting NCT00433719 - Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis N/A
Completed NCT02237365 - A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis Phase 2
Not yet recruiting NCT02588196 - The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Phase 4
Completed NCT03092817 - Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Phase 3
Recruiting NCT03787940 - Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis N/A
Not yet recruiting NCT05917340 - Intensified Short Course Regimen for TBM in Adults Phase 3
Completed NCT01802502 - Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation Phase 2
Recruiting NCT05636254 - Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes
Recruiting NCT03898635 - Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
Active, not recruiting NCT03100786 - Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis Phase 3
Recruiting NCT04145258 - Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis Phase 3
Recruiting NCT05383742 - Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis Phase 2
Completed NCT03226379 - Driving Reduced AIDS-associated Meningo-encephalitis Mortality N/A
Recruiting NCT05590455 - Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis Phase 2
Recruiting NCT04308928 - Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis